Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Tvardi Therapeutics (TVRD) Cost of Revenue (2022 - 2024)

Tvardi Therapeutics' Cost of Revenue history spans 3 years, with the latest figure at $620000.0 for Q1 2024.

  • On a quarterly basis, Cost of Revenue fell 76.06% to $620000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $620000.0, a 89.96% decrease, with the full-year FY2024 number at $620000.0, down 89.96% from a year prior.
  • Cost of Revenue hit $620000.0 in Q1 2024 for Tvardi Therapeutics, up from $608000.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for TVRD hit a ceiling of $3.1 million in Q3 2022 and a floor of $608000.0 in Q4 2023.
  • Historically, Cost of Revenue has averaged $1.8 million across 3 years, with a median of $1.8 million in 2022.
  • Biggest five-year swings in Cost of Revenue: increased 24.46% in 2023 and later crashed 76.06% in 2024.
  • Tracing TVRD's Cost of Revenue over 3 years: stood at $2.1 million in 2022, then plummeted by 71.46% to $608000.0 in 2023, then grew by 1.97% to $620000.0 in 2024.
  • Business Quant data shows Cost of Revenue for TVRD at $620000.0 in Q1 2024, $608000.0 in Q4 2023, and $1.6 million in Q3 2023.